Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 18:17:4805-4814.
doi: 10.2147/IJGM.S480411. eCollection 2024.

Validity of Plasma Neuropeptide Y in Combination with Clinical Factors in Predicting Neuralgia Following Herpes Zoster

Dan Wu  1 , Fang Li  2 , Feifei Yang  3 , Jun Liu  4
Affiliations

Validity of Plasma Neuropeptide Y in Combination with Clinical Factors in Predicting Neuralgia Following Herpes Zoster

Dan Wu et al. Int J Gen Med. .

Abstract

Background: Numerous lines of evidence suggest that neuropeptide Y (NPY) is critically involved in the modulation of neuropathic pain. Postherpetic neuralgia (PHN) is characterized by prolonged duration, severe pain, and significant treatment resistance, substantially impairing patients' quality of life. This study aims to evaluate the potential of plasma NPY levels in patients with PHN as a predictive biomarker for the development of this condition.

Methods: Between February 2022 and December 2023, 182 patients with herpes zoster (HZ) were recruited. Thirty-eight volunteers with no history of HZ were also recruited as controls. Clinical factors, NPY, brain-derived neurotrophic factor (BDNF), and nerve growth factor (NGF) were assessed within 3 days of healing. Logistic regression analysis was used to predict the development of PHN.

Results: NPY levels were lower and BDNF and NGF were higher in HZ patients than those in controls. Only NPY levels were lower in patients with PHN (n = 59) compared with those without PHN (n = 123). Age, acute pain severity, and rash area were independent predictors of PHN, as were NPY levels. The area under the curve (AUC) to predict the development of PHN based on the combination of NPY levels and clinical factors was 0.873 (95% CI: 0.805 to 0.940), and the AUC was 0.804 based on only clinical factors (AUC: 0.804, 95% CI: 0.728 to 0.881).

Conclusion: Low plasma NPY levels are a predictor of developing PHN in patients with HZ. Combining clinical predictors with NPY levels may improve predictive accuracy.

Keywords: herpes zoster; neuropeptide Y; postherpetic neuralgia; sensory neurons.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flowchart of the clinical study.
Figure 2
Figure 2
Comparison of plasma NPY, NGF, and BDNF levels in patients with PHN and patients without PHN. ****P < 0.0001, nsP > 0.05.
Figure 3
Figure 3
Receiver operating characteristic curves using multiple models containing plasma NPY (red) compared to the reference model (green).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Park SY, Kim JY, Kwon J-S, et al. Relationships of varicella zoster virus (VZV)-specific cell-mediated immunity and persistence of VZV DNA in saliva and the development of postherpetic neuralgia in patients with herpes zoster. J Med Virol. 2019;91(11):1995–2000. doi:10.1002/jmv.25543 - DOI - PubMed
    1. Chen L, Zhang Y, Chen Y, et al. Efficacy and safety of botulinum toxin A and pulsed radiofrequency on postherpetic neuralgia: a randomized clinical trial. Contrast Media Mol Imaging. 2022;2022:1579937. doi:10.1155/2022/1579937 - DOI - PMC - PubMed
    1. Liu L, Chen Q, Yang J, et al. Fire needling acupuncture for adult patients with acute herpes zoster: protocol of a systematic review and meta-analysis. J Pain Res. 2022;15:2161–2170. doi:10.2147/JPR.S370484 - DOI - PMC - PubMed
    1. Irving GA, Sweeney M. Tolerability and safety of gastroretentive once-daily gabapentin tablets for the treatment of postherpetic neuralgia. J Pain Res. 2012;5:203–208. doi:10.2147/JPR.S32562 - DOI - PMC - PubMed
    1. Valladales-Restrepo LF, Velasquez-Quimara S, Machado-Alba JE. Pharmacological treatment of herpes zoster and factors associated with its recurrence. Antibiotics. 2023;12(4):757. doi:10.3390/antibiotics12040757 - DOI - PMC - PubMed

LinkOut - more resources